☆ 4.6 Editorial Material

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer

CANCER BIOLOGY & MEDICINE (2022)

Get Full Text
Add to Collection

Journal

CANCER BIOLOGY & MEDICINE
Volume 19, Issue 2, Pages 136-139

Publisher

CHINA ANTI-CANCER ASSOC
DOI: 10.20892/j.issn.2095-3941.2021.0520

Keywords

-

Categories

Oncology Medicine, Research & Experimental

Funding

  1. National Natural Science Foundation of China [81920108025]
  2. Shanghai Municipal Science and Technology Project [20JC1411100]
  3. 111 Project [B21024]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.